Swiss mitophagy specialist Vandria SA has booted its CHF18m Series A financing from December 2023 by further CHF10.3m to push its lead VNA-318 to Phase Ib testing.
https://european-biotechnology.com/wp-content/uploads/2024/08/Biopole-SA-e1724220569755.jpg5401491Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2024-08-21 08:58:372024-08-22 09:15:04Vandria closes Series A round at CHF28.3m